FDAapproval95% confidence
CDER proposes to withdraw approval of TAVNEOS
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Endocrinology · Thyroid Disorders
- Sub-indication
- General
Related signal: FDA Grants Approval for Levothyroxine Sodium ANDA216370 by Alembic